Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer are surgical excision, chemotherapy, and radiation therapy. Immunotherapy ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

Investment analysts at StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research note issued on Saturday. The brokerage set a “hold” rating on ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

This novel approach consists of T cells engineered to express a CAR against p95HER2 and secrete the TECH2Me bispecific antibody that specifically recognizes tumor cells. In addition, this ...

1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York ...

Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics Ltd. has amended its company constitution, highlighting key changes in share capital and shareholder rights. These ...

The research paper titled "Recruiting the Immune System against Pathogenic Bacteria Using High-Affinity Chimeric Tags" is published in the journal Bioconjugate Chemistry. Pathogens often escape ...